Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1976 1
1982 1
1984 1
1985 1
1988 2
1989 2
1990 3
1991 1
1992 4
1993 5
1994 8
1995 3
1996 4
1997 5
1998 8
1999 13
2000 13
2001 13
2002 11
2003 17
2004 11
2005 15
2006 10
2007 18
2008 8
2009 18
2010 17
2011 15
2012 21
2013 25
2014 22
2015 18
2016 10
2017 17
2018 20
2019 23
2020 10
2021 14
2022 14
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 16184376

359 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) to reduce U50,488-induced diuresis and stress-induced cocaine reinstatement in rats.
Beardsley PM, Pollard GT, Howard JL, Carroll FI. Beardsley PM, et al. Psychopharmacology (Berl). 2010 Jun;210(2):189-98. doi: 10.1007/s00213-010-1846-3. Epub 2010 Apr 7. Psychopharmacology (Berl). 2010. PMID: 20372878 Free PMC article.
Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
Thomas JB, Atkinson RN, Vinson NA, Catanzaro JL, Perretta CL, Fix SE, Mascarella SW, Rothman RB, Xu H, Dersch CM, Cantrell BE, Zimmerman DM, Carroll FI. Thomas JB, et al. J Med Chem. 2003 Jul 3;46(14):3127-37. doi: 10.1021/jm030094y. J Med Chem. 2003. PMID: 12825951
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, Forster BM, Wong CJ, Li X, Crile RS, Shaw DB, Sahr AE, Adams BL, Quimby SJ, Diaz N, Jimenez A, Pedregal C, Mitch CH, Knopp KL, Anderson WH, Cramer JW, McKinzie DL. Rorick-Kehn LM, et al. Neuropharmacology. 2014 Feb;77:131-44. doi: 10.1016/j.neuropharm.2013.09.021. Epub 2013 Sep 23. Neuropharmacology. 2014. PMID: 24071566
359 results